HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account

Myeloma News

The HealthTree News for Myeloma is a place to learn all about Myeloma in easy-to-understand language. The site features news articles, patient stories, Myeloma basics articles, and clinical trial updates with new content every week.

New, Friendlier Format to View Past Myeloma Round Tables

Feb. 06, 2023

New, Friendlier Format to View Past Myeloma Round Tables

What are Natural Killer Cells?

Feb. 06, 2023

What are Natural Killer Cells?

ASH 2022: MRD Blood-Based Testing in Multiple Myeloma

Feb. 06, 2023

ASH 2022: MRD Blood-Based Testing in Multiple Myeloma

ASH 2022: Risk-Adapted Therapy and MRD-Guided Strategies in Newly Diagnosed Multiple Myeloma

Feb. 02, 2023

ASH 2022: Risk-Adapted Therapy and MRD-Guided Strategies in Newly Diagnosed Multiple Myeloma

Does Quad Induction Therapy Increase Side Effects in Myeloma When Compared to Triplet Therapy?

Feb. 01, 2023

Does Quad Induction Therapy Increase Side Effects in Myeloma When Compared to Triplet Therapy?

HealthTree Connect: A Larger Network for the Myeloma Community

Feb. 01, 2023

HealthTree Connect: A Larger Network for the Myeloma Community

Clinical Trial: Isatuximab in Monoclonal Gammopathy of Renal Significance (MGRS)

Feb. 01, 2023

Clinical Trial: Isatuximab in Monoclonal Gammopathy of Renal Significance (MGRS)

Save the Date(s): Austin, Indianapolis, Raleigh-Durham Myeloma Round Tables, Spring 2023

Feb. 01, 2023

Save the Date(s): Austin, Indianapolis, Raleigh-Durham Myeloma Round Tables, Spring 2023

White Bean Chili

Jan. 31, 2023

White Bean Chili

ASH 2022: Evaluating Responses to SARS-CoV-2 Vaccination Among Patients with Myeloma

Jan. 29, 2023

ASH 2022: Evaluating Responses to SARS-CoV-2 Vaccination Among Patients with Myeloma

ASH 2022: Talquetamab for Relapsed/Refractory Myeloma Showing Durable Responses

Jan. 24, 2023

ASH 2022: Talquetamab for Relapsed/Refractory Myeloma Showing Durable Responses

ASH 2022: A New Option for High-Risk Smoldering Myeloma Patients

Jan. 24, 2023

ASH 2022: A New Option for High-Risk Smoldering Myeloma Patients

Recent Articles

New in Myeloma

ASH 2022: MRD Blood-Based Testing in Multiple Myeloma image
ASH 2022: MRD Blood-Based Testing in Multiple Myeloma
ASH 2022: Risk-Adapted Therapy and MRD-Guided Strategies in Newly Diagnosed Multiple Myeloma image
ASH 2022: Risk-Adapted Therapy and MRD-Guided Strategies in Newly Diagnosed Multiple Myeloma
ASH 2022: Evaluating Responses to SARS-CoV-2 Vaccination Among Patients with Myeloma image
ASH 2022: Evaluating Responses to SARS-CoV-2 Vaccination Among Patients with Myeloma
ASH 2022: Talquetamab for Relapsed/Refractory Myeloma Showing Durable Responses image
ASH 2022: Talquetamab for Relapsed/Refractory Myeloma Showing Durable Responses
ASH 2022: A New Option for High-Risk Smoldering Myeloma Patients image
ASH 2022: A New Option for High-Risk Smoldering Myeloma Patients
ASH 2022: Elranatamab Bispecific Shows Promise in Multiple Myeloma image
ASH 2022: Elranatamab Bispecific Shows Promise in Multiple Myeloma
Load More

Life With Myeloma

HealthTree Connect: A Larger Network for the Myeloma Community image
HealthTree Connect: A Larger Network for the Myeloma Community
ASH 2022: Improved Quality of Life on Quad Therapy image
ASH 2022: Improved Quality of Life on Quad Therapy
ASH 2022: Cancer Causes Distress. No Duh! image
ASH 2022: Cancer Causes Distress. No Duh!
ASH 2022: Factors Influencing Black Patient Participation in Clinical Trials image
ASH 2022: Factors Influencing Black Patient Participation in Clinical Trials
ASH, Myeloma, and What It Means to You: A Commentary image
ASH, Myeloma, and What It Means to You: A Commentary
ASH 2022: Which Impacts Your MGUS Status - COVID Vaccine or Obesity? image
ASH 2022: Which Impacts Your MGUS Status - COVID Vaccine or Obesity?
Load More

Myeloma Basics

What are Natural Killer Cells? image
What are Natural Killer Cells?
What is Plasma Cell Enrichment and How Does it Help Obtain Better Test Results in Multiple Myeloma? image
What is Plasma Cell Enrichment and How Does it Help Obtain Better Test Results in Multiple Myeloma?
The Role of Maintenance Therapy After Stem Cell Transplant image
The Role of Maintenance Therapy After Stem Cell Transplant
The Personal Impact of a HealthTree Coach: Maddie & Renee's Story image
The Personal Impact of a HealthTree Coach: Maddie & Renee's Story
What Are Neutrophils in Multiple Myeloma? image
What Are Neutrophils in Multiple Myeloma?
Different Types of CAR-T in Multiple Myeloma image
Different Types of CAR-T in Multiple Myeloma
Load More
Patient Stories
articles for Patient Stories
HealthTree Research
articles for HealthTree Research
Clinical Trials
articles for Clinical Trials
HealthTree Press
articles for HealthTree Press
HealthTree
articles for HealthTree
Healthy Recipes
articles for Healthy Recipes

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube

 https://www.guidestar.org/profile/45-5354811

HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2022 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811